↓ Skip to main content

Dove Medical Press

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first- episode or multi-episode schizophrenia

Overview of attention for article published in Neuropsychiatric Disease and Treatment, June 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user
facebook
1 Facebook page
googleplus
1 Google+ user

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
32 Mendeley
Title
Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first- episode or multi-episode schizophrenia
Published in
Neuropsychiatric Disease and Treatment, June 2013
DOI 10.2147/ndt.s45697
Pubmed ID
Authors

Kenji Washida, Toshihiko Takeda, Toshiaki Habara, Soichiro Sato, Takuro Oka, Masuo Tanaka, Yusaku Yoshimura, Shozo Aoki

Abstract

The aim of this study was to examine the speed of response, doses, and safety of treatment with second-generation antipsychotics (SGAs) in patients at ultra-high risk (UHR) compared to those with schizophrenia.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 3%
Unknown 31 97%

Demographic breakdown

Readers by professional status Count As %
Other 5 16%
Student > Master 4 13%
Researcher 4 13%
Student > Ph. D. Student 4 13%
Student > Bachelor 3 9%
Other 4 13%
Unknown 8 25%
Readers by discipline Count As %
Medicine and Dentistry 10 31%
Psychology 8 25%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Veterinary Science and Veterinary Medicine 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 0 0%
Unknown 11 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2013.
All research outputs
#16,046,765
of 25,373,627 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,583
of 3,132 outputs
Outputs of similar age
#119,287
of 206,477 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#26
of 54 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,477 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.